WO2020232394A1 - Microneedle arrays with undercut features for cutaneous and non-cutaneous drug delivery - Google Patents
Microneedle arrays with undercut features for cutaneous and non-cutaneous drug delivery Download PDFInfo
- Publication number
- WO2020232394A1 WO2020232394A1 PCT/US2020/033235 US2020033235W WO2020232394A1 WO 2020232394 A1 WO2020232394 A1 WO 2020232394A1 US 2020033235 W US2020033235 W US 2020033235W WO 2020232394 A1 WO2020232394 A1 WO 2020232394A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microneedles
- microneedle
- microneedle array
- mold
- stem
- Prior art date
Links
- 238000003491 array Methods 0.000 title claims abstract description 15
- 238000012377 drug delivery Methods 0.000 title description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 128
- 239000000463 material Substances 0.000 claims abstract description 121
- 238000000034 method Methods 0.000 claims abstract description 86
- 230000000975 bioactive effect Effects 0.000 claims description 40
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 32
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 32
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 22
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 22
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 22
- 239000011159 matrix material Substances 0.000 claims description 19
- -1 silk Polymers 0.000 claims description 19
- 229920005989 resin Polymers 0.000 claims description 17
- 239000011347 resin Substances 0.000 claims description 17
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 16
- 210000001519 tissue Anatomy 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 11
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 11
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000003106 tissue adhesive Substances 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 239000003193 general anesthetic agent Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 3
- 239000013566 allergen Substances 0.000 claims description 3
- 229940035674 anesthetics Drugs 0.000 claims description 3
- 230000003712 anti-aging effect Effects 0.000 claims description 3
- 230000001387 anti-histamine Effects 0.000 claims description 3
- 229940125715 antihistaminic agent Drugs 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 210000001808 exosome Anatomy 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 239000004055 small Interfering RNA Substances 0.000 claims description 3
- 229940126586 small molecule drug Drugs 0.000 claims description 3
- 238000012876 topography Methods 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 241001077898 Melanthera Species 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 241000700584 Simplexvirus Species 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 238000003618 dip coating Methods 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 54
- 108010058846 Ovalbumin Proteins 0.000 description 46
- 229940092253 ovalbumin Drugs 0.000 description 46
- 238000013461 design Methods 0.000 description 30
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 27
- 239000004205 dimethyl polysiloxane Substances 0.000 description 25
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 25
- 229960005486 vaccine Drugs 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 23
- 238000000879 optical micrograph Methods 0.000 description 20
- 238000002255 vaccination Methods 0.000 description 19
- 230000003053 immunization Effects 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 238000002649 immunization Methods 0.000 description 17
- 101150067597 treh gene Proteins 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 229920001971 elastomer Polymers 0.000 description 15
- 239000000806 elastomer Substances 0.000 description 15
- 239000004372 Polyvinyl alcohol Substances 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 238000001053 micromoulding Methods 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 238000013459 approach Methods 0.000 description 12
- 239000004191 allura red AC Substances 0.000 description 11
- 235000012741 allura red AC Nutrition 0.000 description 11
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 11
- 239000000975 dye Substances 0.000 description 11
- 230000035515 penetration Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000004528 spin coating Methods 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 238000011960 computer-aided design Methods 0.000 description 6
- 239000000017 hydrogel Substances 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 238000000465 moulding Methods 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 6
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229920002120 photoresistant polymer Polymers 0.000 description 5
- 238000010146 3D printing Methods 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 238000000339 bright-field microscopy Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000007639 printing Methods 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 238000007648 laser printing Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000001459 lithography Methods 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- LLHKCFNBLRBOGN-UHFFFAOYSA-N propylene glycol methyl ether acetate Chemical compound COCC(C)OC(C)=O LLHKCFNBLRBOGN-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- OUOAFMZIPXCUBR-UHFFFAOYSA-N 4-(4-amino-3,4-dimethylcyclohexa-2,5-dien-1-ylidene)-1,2-dimethylcyclohexa-2,5-dien-1-amine Chemical compound C1=CC(N)(C)C(C)=CC1=C1C=C(C)C(C)(N)C=C1 OUOAFMZIPXCUBR-UHFFFAOYSA-N 0.000 description 1
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010073753 Fear of injection Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000005459 micromachining Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C33/00—Moulds or cores; Details thereof or accessories therefor
- B29C33/38—Moulds or cores; Details thereof or accessories therefor characterised by the material or the manufacturing process
- B29C33/3835—Designing moulds, e.g. using CAD-CAM
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C33/00—Moulds or cores; Details thereof or accessories therefor
- B29C33/38—Moulds or cores; Details thereof or accessories therefor characterised by the material or the manufacturing process
- B29C33/3842—Manufacturing moulds, e.g. shaping the mould surface by machining
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C33/00—Moulds or cores; Details thereof or accessories therefor
- B29C33/44—Moulds or cores; Details thereof or accessories therefor with means for, or specially constructed to facilitate, the removal of articles, e.g. of undercut articles
- B29C33/48—Moulds or cores; Details thereof or accessories therefor with means for, or specially constructed to facilitate, the removal of articles, e.g. of undercut articles with means for collapsing or disassembling
- B29C33/50—Moulds or cores; Details thereof or accessories therefor with means for, or specially constructed to facilitate, the removal of articles, e.g. of undercut articles with means for collapsing or disassembling elastic or flexible
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
- B29K2105/0035—Medical or pharmaceutical agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
- B29K2995/0037—Other properties
- B29K2995/0059—Degradable
- B29K2995/006—Bio-degradable, e.g. bioabsorbable, bioresorbable or bioerodible
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
- B29K2995/0037—Other properties
- B29K2995/0059—Degradable
- B29K2995/0062—Degradable water-soluble
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/753—Medical equipment; Accessories therefor
- B29L2031/7544—Injection needles, syringes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/756—Microarticles, nanoarticles
Definitions
- This disclosure is directed to microneedle arrays and, in particular, to microneedle arrays formed with undercut features for cutaneous and non-cutaneous drug delivery, as well as for tissue adhesive patches.
- the skin is a readily accessible tissue with many distinct functions such as serving as a protective barrier and a thermal regulator. Remarkably, the skin also functions as an active immune organ. For some purposes, such as immunization, cancer immunotherapy, and allergy
- the skin can be preferred anatomic target site since it harbors large populations of professional antigen-presenting and immune- accessory cells.
- Most vaccines, immune modifiers, and cancer drugs are administered using hypodermic needle-based injections.
- drug delivery using traditional syringes is associated with several disadvantages. These include requirement for trained healthcare personnel for administration, trypanophobia (i.e., fear of needles), poor patient compliance, risk of disease transmission and needle-stick injuries, and costs of cold chain storage and transport.
- microneedle arrays are manufactured with undercut features for cutaneous and non-cutaneous drug delivery, as well as for tissue adhesive patches.
- a method of forming a microneedle array comprises forming a production mold of a flexible material having plurality of cavities that are shaped to define a plurality of respective microneedles that each have a stem, a microneedle tip, a filleted base, and at least one undercut feature, incorporating at least one bioactive material into a first dissolvable material to provide a biodegradable matrix, delivering the biodegradable matrix into at least the microneedle-tip portion defined by the respective cavities of the production mold, forming a plurality of microneedles in the production mold that include the biodegradable matrix, and removing the microneedles from the production mold by pulling the microneedles out of the mold.
- the flexible material can have sufficient elasticity to allow for the molded microneedle array to be removed from the production mold in a single pull without damaging the integrity of the shape of the microneedles as defined by the mold.
- a microneedle array is formed using a single-pull mold comprising a backing layer, a plurality of microneedles, and at least one bioactive material combined with a first dissolvable material to form a biodegradable matrix.
- the plurality of microneedles each have a stem, a microneedle tip, a filleted base, and at least one undercut feature.
- a method of forming a mold comprises generating a 3D-CAD drawing of a microneedle array that includes a plurality of microneedles with at least one undercut feature, forming a master microneedle array using the 3D-CAD drawing, forming at least one replica of the master microneedle array, and forming a production mold of the microneedle array using the at least one replica.
- the production mold is formed of a flexible material.
- FIG. 1 illustrates exemplary microneedle designs that have, in these examples, sharp-tipped conical heads, circular undercut stems, and filleted bases.
- FIGS. 2A-C illustrate a microneedle array that is formed with a conformable backing layer.
- FIG. 3A discloses a computer-aided design (CAD) drawing of an exemplary the MNAs that include sharp needles with undercut features and filleted bases.
- CAD computer-aided design
- FIG. 3B discloses a 3D CAD drawing of an exemplary MNA with a 5x5 needle arrangement.
- FIG. 4A discloses a flow chart for an exemplary MNA manufacturing process.
- FIG. 4B illustrates the different steps of the exemplary MNA manufacturing process in FIG. 4A.
- FIG. 5A shows an optical microscope image of a master MNA created using 3D direct laser writing.
- FIG. 5B shows an optical microscope image of the replica of the master MNA created through a two-stage micromolding strategy.
- FIG. 5C shows an optical microscope image of the microneedle-shaped wells in MNA production molds.
- FIG. 5D shows an optical microscope image of an individual undercut needle on the 3D printed master MNA.
- FIG. 5E shows an optical microscope image of an individual undercut needle on the replica of a master MNA.
- FIG. 6A shows an optical microscope image of final dissolving (CMC/Treh) MNAs incorporating biocargos (e.g., OVA+Poly(I:C)).
- CMC/Treh final dissolving MNAs incorporating biocargos
- FIG. 6B shows an optical microscope image of dissolving, tip-loaded PVP/PVA MNAs with undercut microneedles integrating OVA.
- FIG. 6C shows an optical microscope image of an individual tip-loaded CMC/Treh undercut microneedle incorporating Doxorubicin as a colored drug to facilitate imaging.
- FIG. 7A shows PVP/PVA MNAs incorporating Texas Red labeled Dextran (approximately 40 kDa molecular weight) at the tips of microneedles.
- FIG. 7B shows tip-loaded CMC/Treh MNAs integrating Allura Red R40 dye
- FIG. 7C shows tip-loaded PVP/PVA MNAs incorporating multiple cargos such as Texas Red labeled Dextran and Allura Red R40 dye.
- FIG. 7D shows tip-loaded PVP/PVA MNAs incorporating multiple cargos such as Texas Red-labeled Dextran and Alexa488-labeled PLGA microparticles (10 pm mean diameter).
- FIG. 8A illustrates different microneedle designs fabricated from IP-S photoresist using 3D direct laser writing.
- FIG. 8B illustrates images of printed microneedles with filleted bases.
- FIG. 9A optical microscope images of the PVP/PVA-MNAs incorporating Allura Red dye before human skin application.
- FIG. 9B shows bright-field microscope image of Allura Red R40 dye microneedle traces on living human skin samples.
- FIG. 9C shows optical microscope images of the PVP/PVA-MNAs incorporating Allura Red dye after human skin application.
- FIGS. 9D-I show intradermal co-delivery of Alexa488-labeled Poly(FC) and Alexa555- labeled OVA from tip-loaded CMC/Treh MNAs. 20x optical magnification. Fluorescence microscope composite images demonstrate delivery cavities penetrating the epidermis and upper dermis, and delivery of both the antigen and adjuvant to targeted skin microenvironments.
- FIG. 10A shows an optical microscope images of MNAs integrating both Alexa555-OVA and Alexa488-Poly(I:C), with the fluorescent image being a representative figure of the pyramid head incorporating both cargos.
- FIG. 10B shows representative optical microscope images of the Alexa555-OVA and Alexa488-Poly(I:C)- loaded MNAs after an in vivo application to the depicted mouse.
- FIG. IOC and 10D show the effective co-delivery of Alexa488-Poly(I:C) and Alexa555- OVA to the skin microenvironments using novel MNAs.
- FIG. 11A illustrates representative histograms from flow cytometry analysis showing remaining CFSE-labeled cells in spleens of immunized and unimmunized mice.
- FIG. 1 IB shows quantification of specific cell lysis, with 100% lysis corresponding to complete elimination of target cells (mean ⁇ SD, 3 mice per group).
- FIG. l lC shows serum concentrations of OVA-specific IgGl and IgG2c antibodies (bars represent mean values, 3 mice per group).
- MNAs microneedle arrays
- biological refers to pharmaceutically active agents, such as analgesic agents, anesthetic agents, anti asthmatic agents, antibiotics, anti-depressant agents, anti-diabetic agents, anti-fungal agents, anti hypertensive agents, anti-inflammatory agents, anti-neoplastic agents, anxiolytic agents, enzymatically active agents, nucleic acid constructs, immunostimulating agents,
- pharmaceutically active agents such as analgesic agents, anesthetic agents, anti asthmatic agents, antibiotics, anti-depressant agents, anti-diabetic agents, anti-fungal agents, anti hypertensive agents, anti-inflammatory agents, anti-neoplastic agents, anxiolytic agents, enzymatically active agents, nucleic acid constructs, immunostimulating agents,
- the bioactive material can comprise dissoluble materials, insoluble but dispersible materials, natural or formulated macro, micro and nano particulates, and/or mixtures of two or more of dissoluble, dispersible insoluble materials and natural and/or formulated macro, micro and nano particulates.
- any other suitable bioactive material such as those discussed above, can be used in the novel MNA designs.
- pre-formed means that a structure or element is made, constructed, and/or formed into a particular shape or configuration prior to use. Accordingly, the shape or configuration of a pre-formed microneedle array is the shape or configuration of that microneedle array prior to insertion of one or more of the microneedles of the microneedle array into the patient.
- undercut or“undercut feature” refers to a recessed surface that is deemed to be inaccessible using standard molding methods and, in particular, to a feature (e.g., an indentation, protrusion, or other geometric shape) that restricts or prevents the withdraw of a molded part having this feature from a conventional one-piece mold.
- a feature e.g., an indentation, protrusion, or other geometric shape
- the singular forms“a,”“an,” and“the” include the plural forms unless the context clearly dictates otherwise.
- the term“includes” means“comprises.”
- the term“and/or” means any one item or combination of items in the phrase.
- the term“exemplary” means serving as a non-limiting example, instance, or illustration.
- the terms“e.g.,” and“for example,” introduce a list of one or more non-limiting embodiments, examples, instances, and/or illustrations.
- microneedle arrays have many advantages over conventional needle-based injection techniques. For this reason, cutaneous vaccination or drug delivery using microneedle arrays offers a viable and attractive approach to effective immunization or cancer immunotherapy due to the aforementioned theoretical advantages of the skin.
- MNAs physically penetrate the stratum corneum, thereby eliminating formulation complexities and resulting in localized deposition of vaccines or drugs in the skin microenvironments.
- the microneedles are benign to pain receptors, enabling minimally-invasive pain- free immunization.
- MNAs can provide highly effective vaccination due to their higher antigen loading capacity, tunable release kinetics, simple manufacturing, and long-term stability.
- Such MNAs can be created from water-soluble polymers that dissolve when inserted into the skin.
- the microneedles of MNAs are preferably strong enough in their dry-state to penetrate the stratum comeum, and then rapidly dissolve in the fluid environment of the skin, thereby releasing vaccines. Precise delivery of bioactive materials, such as vaccines, to the cutaneous
- microenvironments can result in improved efficiencies, thereby requiring relatively lower doses compared to traditional needle injections.
- microneedles with undercut geometries that include dissolvable and/or non-dissolvable materials can be formed by the novel methods and systems described herein.
- the novel MNAs can be formed via a single-step micromolding process that utilizes flexible production mold materials.
- the use of such flexible production mold materials allows for the production of a range of geometric designs not otherwise possible.
- the flexible production mold material can comprise, for example, any elastomer or other flexible material that allows for the removable of the microneedles of a desired design (e.g., a desired amount of undercut and/or other geometric shape).
- the ability to mold a variety of geometric shapes that are otherwise difficult to manufacture by molding enables novel and innovative functionally-graded MNAs, such as the ones shown in FIG. 1, for targeted delivery of a variety of bioactive materials to skin and other tissues (e.g., cardiac and ocular tissue).
- FIG. 1 illustrates examples of different structures of microneedles that can be formed using the methods and systems described herein.
- four different microneedle structures 10, 12, 14, 16 are shown in a production mold 18 that is formed from a flexible material, such as a flexible elastomer.
- Microneedle 10 is formed with a dissolvable backing layer 20, a dissolvable stem 22, and a microneedle tip 24 that is loaded with a bioactive material.
- microneedle 10 is fabricated from a dissolving (or biodegradable) material throughout.
- the bioactive material can be mixed into the dissolving material, but is preferably located at the tip of the needles as shown in FIG. 1 to improve delivery efficiency.
- microneedles 10, 12, 14, 16 can have a pyramid head-shape with a sharp tip and an undercut stem that connects to a backing layer through filleted bases.
- Fillets 32 can provide improved mechanical performance during tissue insertion.
- the MNAs described herein can be fabricated from any moldable dissolving,
- biodegradable, and/or biocompatible, non-dissolvable materials including carboxymethylcellulose, trehalose, polyvinylpyrrolidone, poly(vinyl alcohol), maltodextrin, silk, glucose, hyaluronic acid, poly(methyl methacrylate), polycarbonate, poly(lactic-co-glycolic acid), poly(lactic acid), light curable resins, and their combinations to incorporate any bioactive materials, including cosmetics, dermal-fillers, statins, growth factors, pain killers, anti-histamines, vitamins, anesthetics, anti-aging agents, small molecule drugs, haptens, allergens, anti-inflammatory agents, proteins, peptides, micro vesicles, exosomes, polyplexes (siRNA, shRNA, DNA vector complexes), recombinant viral vectors (i.e., Adenovirus, Lentivirus, Vaccinia Virus, Adeno-Associated Virus, and their different serotypes),
- Microneedle 12 is formed with a non-dissolvable backing layer 26, a non-dissolvable stem 28, and a microneedle tip 24 that is loaded with a bioactive material.
- This functionally-graded, undercut MNA design can be fabricated with more than one material.
- the pyramid portion can be created using a dissolving or biodegradable material, while the stem portion and the backing layer are manufactured from a non-dissolvable material, such as a non-dissolvable biocompatible rigid polymer (e.g., poly(methyl methacrylate), polycarbonate, Vero White and other UV-curable and heat curable resins).
- a non-dissolvable biocompatible rigid polymer e.g., poly(methyl methacrylate), polycarbonate, Vero White and other UV-curable and heat curable resins.
- Microneedle 12 can, therefore, provide a sharp needle tip along with enhanced mechanical performance through a filleted base enables successful tissue penetration and a pyramid head that serves as the bioactive material dosage form where the bioactive material(s) are incorporated into a dissolving or degrading biomaterial matrix.
- the undercut stem portion improves the mechanical performance during penetration while ensuring tissue retention during implantation and the non- dissolvable undercut stem portion prevents back diffusion of the embedded bioactive material(s) during both fabrication and implantation processes.
- the non-dissolvable backing layer can also help prevent absorption of humidity during storage, which may result in excessive curvature of the backing layers and render MNA applications suboptimal.
- Microneedle 14 is similar in shape to microneedles 12, 14, but further includes another dissolving layer 30.
- the pyramid portion is created using a dissolving or
- the dissolving layer can be formed for example, from a small molecular weight quickly dissolving polymer such as glucose, sucrose, trehalose, maltodextrin, or
- the rest of the stem portion and the backing layer can be formed from a non- dissolvable material, such as a non-dissolvable biocompatible rigid polymer such as acrylated polyesters, epoxies, UV-curable monomers, resins, silicones.
- a non-dissolvable biocompatible rigid polymer such as acrylated polyesters, epoxies, UV-curable monomers, resins, silicones.
- Microneedle 14 therefore provides a sharp needle tip along with enhanced mechanical performance through a filleted base enables successful tissue penetration, a pyramid head that serves as the bioactive material dosage form where the bioactive material(s) are incorporated into a dissolving or degrading biomaterial matrix, an undercut stem portion improves the mechanical performance during penetration while ensuring tissue retention during implantation, and a quickly dissolving layer along with the mechanical mismatch between dissolving and non-dissolving layers that facilitates quick separation of pyramid tips.
- Microneedle 16 is similar to microneedle 14 but further comprises a conforming backing layer 34, which may be non-dissolvable.
- microneedle 16 can be formed with a pyramid portion that is created using a dissolving or biodegradable material, the quickly dissolving layer can be formed as described above, the rest of the stem portion can be manufactured from a non-dissolvable material, and the backing layer can be manufactured from a conformable material, such as a non-dissolvable conformable polymer (silicones, UV-curable polymers, elastomers).
- Microneedle 16 can therefore provide a sharp needle tip along with enhanced mechanical performance through a filleted base enables successful tissue penetration, a pyramid head that serves as the bioactive material dosage form where the bioactive material(s) are incorporated into dissolving or degrading biomaterial matrix, and an undercut stem portion that improves the mechanical performance during penetration while ensuring tissue retention during implantation,
- the quickly dissolving layer along with the mechanical mismatch between dissolving and non-dissolving layers can facilitate quick separation of pyramid tips and the non- dissolvable undercut stem portion prevents back diffusion of the embedded bioactive material during both fabrication and implantation processes.
- the backing layer can conform to non-uniform skin topography better and, if non-dissolvable, it can help prevent absorption of humidity which may result in excessive curvature of the backing layers and render MNA applications suboptimal.
- FIG. 2A-2C illustrate the ability of a microneedle array 50 that has microneedles 52 and a conformable backing layer 34 to bend, and after bending return to an original state, or at least a state that is closer in shape to the original state than the bent state.
- the conformable backing layer of microneedle 16 and the quickly dissolving layer 30 of microneedles 14, 16 can be used in combination with any of the other structures disclosed herein (e.g., microneedles 10, 12).
- the processes disclosed herein can be used to create a microneedle that is formed entirely from non-dissolving materials for use as a coated MNAs, tissue adhesives
- Non-dissolvable undercut microbarb or microneedle geometries have been created previously using additive manufacturing or mechanical micromachining processes. However, high-throughput manufacturing of those geometries is hindered due to lack of effective micromolding processes.
- the MNAs can be formed using additive manufacturing (AM), including micro-additive manufacturing (mAM) techniques.
- AM additive manufacturing
- mAM micro-additive manufacturing
- the methods and systems described herein can allow medical researchers with little microfabrication expertise to directly produce their MNA designs from a computer-aided design (CAD) drawing without the complex requirements of the subtractive fabrication processes.
- CAD computer-aided design
- the mAM techniques described herein provide an effective means for fabrication of novel MNAs designed specifically for effective cutaneous and non- cutaneous drug delivery.
- the MNA designs included uniquely-shaped micron-scale needles that comprising sharp pyramid heads and undercut stems with filleted bases to ensure successful skin penetration and retention.
- the MNAs disclosed herein are fabricated by a three-dimensional (3D) pAM approach with 3D direct laser writing, which offers transformative potential for the MNA field with its unparalleled level of simplicity and design capabilities.
- replicas of the master MNAs can be obtained from a mechanically-strong, moldable resin by a two-step micromolding approach with high fidelity. These replicas can then be used to prepare productions molds, such as
- PDMS polydimethylsiloxane
- a plurality of master MNAs can be printed, replicas of the master MNAs quickly obtained, and then the plurality of replicas can be assembled together to create larger MNAs.
- the MNAs can incorporate a model antigen Ovalbumin (OVA) ⁇ a model adjuvant Poly(I:C) from a biodissolvable material composition (70%CMC/30%Treh) using a spin-casting method.
- Ovalbumin Ovalbumin
- a model adjuvant Poly(I:C) from a biodissolvable material composition (70%CMC/30%Treh) using a spin-casting method.
- FIGS. 3A and 3B illustrate an exemplary microneedle array (MNA) (100) that comprises microneedles with a sharp-tipped pyramid head (102) and an undercut stem portion (104).
- MNA microneedle array
- the microneedles include a filleted base (106).
- the methods and systems disclosed herein enable reproducible fabrication of high-quality, tip-loaded dissolving MNAs with undercut features from different and widely-used dissolving microneedle materials, including CMC, PVP, Silk, HA, CMC/Trehalose, CMC/Glucose,
- the microneedle has a height (110) that is between 50-1500 pm, such as 750 pm in height, and an apex angle (A) of the pyramid head that is between 10°-60, such as 30°.
- the stem portion of the microneedle can have a width (112) that is between 50-500 pm, such as 150 pm.
- the stem portion (104) can extend from the bottom region of a three-dimensional (3D) pyramid head to a backing layer (108) of the microneedle with a radius filleted connection that ranged from 15-75 pm, such as 35 pm.
- a width (114) of the bottom region of the pyramid head can be, for example, between 100-400 pm, such as 250 pm x 250 pm base area.
- the tip-to-tip distance (116) between the microneedles in the array can be between 100-800 pm, such as 650 pm.
- the MNA can include between 1-1000 microneedles, such as 25 microneedles in a 5x5 array configuration on a backing layer with an area of 4.75 mm x 4.75 mm.
- the fillet at the microneedle base (106) can help reduce the associated mechanical stress concentrations at sharp corners, and in turn, increases the microneedle performance during manufacturing processes and skin insertion.
- the apex angle, the width, and the height of the microneedles were selected to provide improved skin insertion mechanics and to reduce failures in penetration.
- the undercut, or anchor feature can improve skin retention during application and, using the novel methods and systems disclosed herein, can be achieved without also interfering with the processing steps, thereby allowing direct removal of the MNAs from the molds.
- 3D-pAM three-dimensional micro-additive manufacturing
- Exemplary manufacturing systems and processes are presented in a flow chart in FIG. 4A and graphically illustrated in FIG. 4B.
- the process can comprise the following steps to create novel fast-dissolving MNAs while simultaneously achieving high- throughput fabrication.
- a 3D-CAD drawing (132) of the MNA design can be prepared (process step 120).
- a direct production of the master MNA (134) from the CAD drawing can be produced by 3D direct laser writing using a non-dissolvable resin (e.g., IP-S photoresist) (process step 122).
- the 3D-pAM manufacturing system can be, for example, a Nanoscribe 3D printing system (136).
- a quick and high-fidelity replication of the master MNA can be formed with a UV- curable resin (e.g., VeroWhitePlus, Tangoblack, Digital Materials) using a two-step micromolding approach (process step 124).
- This approach can include a negative elastomer mold (138) to form the replica (140) of the master MNA.
- the MNA master molds can be created with multiple master MNA replicas (e.g., six replicas) onto 3D-printed MNA holders (process step 126).
- the 3D printed MNA holder (142) can be formed of, for example, a resin material.
- the combination of a plurality of master MNA replicas together onto, for example, 3D-printed MNA holders can allow for the creation of larger MNAs and improve productivity.
- the MNA production molds (144) can be manufactured from the elastomer PDMS using micromolding (process step 128).
- Sixth, tip-loaded, dissolving MNAs (150) can be fabricated (process step 130).
- the MNAs can have undercut microneedles incorporating one or more bioactive material, such as a vaccine or any other bioactive material from a water-soluble biocompatible material (e.g., a composition of CMC and Treh) through a multiple-step spin-casting method using a centrifuge.
- a bioactive component e.g., vaccine
- the dissolvable hydrogel e.g., CMC/Trehalose
- the master MNA, the MNA master molds including replicas of the master MNA, and the elastomer production molds can be reused for a large number of processing cycles, thereby greatly reducing the fabrication costs for MNAs with unique designs and improving productivity.
- FIGS. 5A-5E show final products corresponding to different manufacturing or processing steps.
- FIG. 5A shows an optical microscope image of the master MNA (134) created using 3D direct laser writing and
- FIG. 5D shows an optical microscope image of an individual undercut needle on the 3D printed master MNA (134).
- the master MNA was fabricated from IP- S photoresist by 3D direct laser writing.
- IP-S is a specific material designed for 3D laser lithography and provides high resolution and mechanical integrity for micro- and nano- structures.
- 3D laser lithography based on two-photon polymerization provided an effective means for fabrication of undercut MNA designs with smooth edges and sharp tips, and without any unwanted residues (e.g., machining chips).
- FIG. 5B shows an optical microscope image of the replica (140) of the master MNA created through a two-stage micromolding strategy: elastomer molding combined with UV-curable micromolding
- FIG. 5E shows an optical microscope image of an individual undercut needle on the replica (140) of the master MNA.
- the master MNA was produced using a two-step
- Vero White resin is a wear-resistant, acrylic -based photo-polymer that can be used with 3D Polyjet printers.
- MNA replicas were then used to create MNA master molds that include a number of MNAs (e.g., six MNA replicas).
- the final MNA master molds were post-processed in a vacuum oven to facilitate successful curing of PDMS on the mold surface and then the elastomer MNA production molds, which consisted of microneedle-shaped wells, were fabricated from PDMS.
- FIG. 5C shows an optical microscope image of the microneedle- shaped wells in MNA production molds (144).
- dissolving MNAs that incorporated the vaccine (10 pg OVA+25 pg Poly(I:C)) in the tip portion of the undercut needles were fabricated through the spin casting process from two different material compositions (i.e., CMC/Trehalose and PVP/PVA). Furthermore, tip- loaded CMC/Trehalose MNAs with undercut microneedles integrating a colored model drug (e.g., Doxorubicin) were fabricated to facilitate imaging and demonstrate compatibility with chemotherapeutic agents.
- the systems and methods described herein enabled effective and rapid fabrication of tip-loaded dissolving MNAs with undercut microneedles from different dissolvable material compositions.
- FIG. 6A shows an optical microscope image of final dissolving (CMC/Treh) MNAs incorporating biocargos (e.g., OVA+Poly(I:C)).
- FIG. 4B shows an optical microscope image of dissolving, tip-loaded PVP/PVA MNAs with undercut microneedles integrating OVA
- FIG. 4C shows an optical microscope image of an individual tip-loaded CMC/Treh undercut microneedle incorporating Doxorubicin as a colored drug to facilitate imaging.
- a unique MNA design was directly created from the 3D-CAD drawing shown in FIG. 1 using 3D laser printing (Nanoscribe Photonic Professional, GT) with the photopolymetric resist IP-S.
- the Nanoscribe printing system was equipped with a laser generator, an optical cabinet, a Zeiss optical microscope attached to a lens to focus the laser beam, a Galvo mirror system to direct the laser-beam scanning, a piezoelectric stage for precise motion control, and an operation software (Nanowrite) to execute 3D printing. The whole system was placed on an optical table to eliminate vibrations during the printing process.
- StepoLithography (StereoLithography) format. Subsequently, the STL file was loaded into the specialized software (DeScribe, Germany) of the Nanoscribe system to select the processing conditions (i.e., the distance of slicing, hatching, and splitting). Finally, the STL file was converted into‘GWL’ (General Writing Lithography) format to be exported in the Nanowrite software for printing the master MNA.
- the master MNA was fabricated using Galvo-scan mode in XY plane and piezo-scan mode in Z direction. The master MNA was split into blocks of 220 pm x 220 pm x 200 pm within the working range and then stitched together. The laser power and writing speed was set to be 100 mW and 6 cm/s, respectively.
- the master MNA was then printed through two-photon polymerization of the IP-S photoresist by a femtosecond pulsed laser at a wavelength of 750 nm using a unique deep- in- liquid mode with the objective of 25x and NA0.8 in Shell and Scaffold mode.
- the master MNA was developed in the photoresist solvent propylene glycol monomethyl ether acetate (PGMEA) for 30 min, followed by 5 min isopropyl alcohol (IP A) rinse. After the master MNA was dried in the air, it was placed under a UV (365 nm) light with 16 mW/cm2 intensity for 30 min to further crosslink the body to strengthen the MNA structure.
- PGMEA photoresist solvent propylene glycol monomethyl ether acetate
- IP A isopropyl alcohol
- the master MNA was mounted in a petri-dish with a diameter of 5 cm and PDMS was obtained using the two-component curable silicone elastomer, SYLGARD® 184 (Dow Corning), by mixing the base material with a curing agent in 10:1 SYLGARD®-to-curing agent ratio. Subsequently, the mixture was poured over the master MNA mounted into the petri-dish and degassed for 15 min. Next, the master MNA with the degassed mixture was placed in an oven and cured at 70 °C for 1 h. The cured PDMS was cooled down to room temperature for 5 min and then separated from the master MNA to obtain the negative PDMS mold.
- SYLGARD® 184 Low Corning
- the second processing step used the negative PDMS mold for fabrication of positive MNA replicas from the UV-curable resin (Stratasys® , VeroWhiteplus-RGD835).
- the UV-curable resin (Stratasys® , VeroWhiteplus-RGD835).
- 20 pi of liquid (uncured) resin was poured onto the molds and then the molds were placed in a centrifuge to fill the microneedle- shaped wells with the resin at 4500 RPM and at 20 °C for 1 min.
- the resin was then cured under UV light (365 nm) with 21.7 mW/cm2 intensity for 5 min from each of the top and bottom sides to cure both the base and the microneedle tips.
- the MNA master molds were created through assembling six replicas of the master MNA onto the MNA holders fabricated by Stratasys® from a non-dis solvable photo-polymer (Vero White) using a high-resolution (16 pm) Polyjet 3D printing system (Objet Connex 500 multi-material).
- the 3D model of the MNA holders created using SolidWorks 2018 CAD software and then converted into the‘STL’ (StereoLithography) file format.
- the specialized software (Objet Studio) sliced this 3D model into 2D cross-sectional layers, creating a computer file that was sent to the 3D printer system.
- the channels in the 3D printed MNA holder were designed and fabricated to serve as raised pockets in the MNA production molds to assist as reservoirs for both the bioactive cargo (e.g., vaccine) and the structural hydrogel material of dissolving MNAs during the spin-casting process.
- the created MNA master molds were baked at 80 °C overnight in a vacuum oven to facilitate effective fabrication of elastomer MNA production molds.
- MNA production molds The MNA production molds that included microneedle-shaped wells were fabricated from a commonly-used elastomer polydimethylsiloxane (PDMS) as described for the replication of the MNA master.
- the base material was mixed with a curing agent in 10:1 SYLGARD®-to-curing agent ratio. Subsequently, the mixture was poured over the MNA master mold placed in a 10 cm diameter petri-dish and degassed for 15 min. Next, the master mold with the degassed mixture was placed in an oven to cure PDMS at 70 °C for 1 h. After cooling down the cured PDMS to room temperature, it was separated from the MNA master mold to fabricate the PDMS MNA production molds.
- PDMS elastomer polydimethylsiloxane
- OVA solution 25 mg/mL OVA in endotoxin-free water
- the production molds were centrifuged for 1 min at 20 °C and at 4500 rpm to fill the microneedle-shaped cavities.
- the excess OVA solution within the reservoir was recovered.
- the production molds were again centrifuged for 30 min at 20 °C and at 4500 rpm to ensure that dry OVA cargo was located at the tip portion of the needle-shaped cavities in the production molds.
- the production molds were again centrifuged for 30 min at 20 °C and at 4500 rpm to ensure that Poly(I:C) cargo was also located at the pyramid portion of the needle-shaped cavities in the production molds.
- 40 pL of hydrogel (30% w/w 70:30 CMC:Treh) was loaded over each of the MNAs on the PDMS production molds to fill the microneedle- shaped geometries in the production molds and to form the backing layers of the MNAs.
- hydrogel-loaded production molds were then centrifuged for 5 h at 20 °C and at 4500 rpm to obtain dissolving MNAs loaded with 10 pg OVA+25 pg Poly(I:C). Due to the specific geometry of the MNA production molds, each replication produced six arrays of OVA ⁇ Poly(I:C)-loaded dissolving MNAs simultaneously.
- Polyvinylpyrrolidone (PVP) and Polyvinyl alcohol (PVA) (40% w/w 60:40 PVP:PVA) was also used to fabricate MNAs with different biocargos.
- the fabricated master MNAs, replicas of MNAs, elastomer MNA production molds, and OVA ⁇ Poly(I:C)-loaded dissolving MNAs were imaged using bright-field optical microscopy to assess geometric integrity of the novel microneedles with undercut features.
- Human skin explants were prepared from deidentified healthy donors undergoing plastic surgery acquired through the Pitt Biospecimen Core and used according to University of Pittsburgh Medical Center guidelines. Tissue was rinsed in 70% ethanol and then in phosphate-buffered saline (PBS). Human skin explants (approximately 1 mm thick) were harvested using a Silver’ s miniature skin graft knife (Padgett, Integra Miltex, Plainsboro, NJ), and then cut into 20 mm x 20 mm square pieces. The resulting human skin samples were comprised of unaltered epidermis and a thin layer of underlying dermis, and maintained as explants in normal physiological state by culture at an air-fluid interface.
- PBS phosphate-buffered saline
- Imaging analysis To evaluate MNA-directed intradermal bioactive materials (e.g., vaccine) delivery to living human skin explants, a number of imaging analyses was performed. Tip- loaded CMC/Treh-MNAs integrating a colored cargo (i.e., Allura Red R40 dye) were fabricated using the manufacturing strategy described above. Prior to application of MNAs to the human skin explants, MNAs were imaged using bright-field optical microscopy.
- a colored cargo i.e., Allura Red R40 dye
- MNAs were applied to human skin explants and removed after 10 min.
- the targeted human skin regions were then examined under a bright-field microscope to image the patterns of the colored biocargo deposited from CMC/Treh-MNAs into the human skin. Remaining MNA materials were also imaged using optical microscopy after human skin applications.
- CMC/Treh MNAs that incorporate both Alexa555-labeled OVA and Alexa488-labeled Poly(I:C) were fabricated, applied to human skin for 10 min, and removed. The targeted human skin explants were then histologically analyzed.
- the MNA-treated human skin samples were fixed in 2% paraformaldehyde followed by immersion in sucrose solution, with 3 changes of this solution over 24 h. Tissue sections were then flash frozen in optimum cutting temperature (OCT) histology compound, and cryo-sectioned into approximately 10 pm thick sections. The sectioned human skin samples were counter- stained using nuclear DAPI fluorescent dye. The stained sections were then imaged using a Nikon transmission fluorescent microscope to detect Alexa555-OVA and
- Alexa488-Poly(I:C) into the cross-sections of human skin, as well as using bright field microscope to better demonstrate the stratum comeum breaching.
- mice and animal husbandry Female C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and used at 8-10 weeks of age. Mice were maintained under specific pathogen-free conditions at the University of Pittsburgh, and all experiments were conducted in accordance with the institutional animal care and use committee (IACUC) guidelines.
- IACUC institutional animal care and use committee
- Imaging of the MNA-treated mouse was performed on the IVIS 200 in vivo imaging system (PerkinElmer) using the filters to assay for fluorescent-labeled Poly(I:C) and OVA the MNA application site.
- the image was post-processed using Living Image software
- OVA-specific antibody response blood was collected from anesthetized mice at the time of sacrifice by cardiac puncture, and serum was isolated using BD Microtainer serum separator tubes (BD Biosciences, San Jose, CA). OVA-specific IgGl and IgG2c antibodies in serum were measured by indirect ELISAs. Costar EIA/RIA plates (Corning Inc., Corning, NY) were coated with OVA (100 pg/mL in 0.5 M carbonate-bicarbonate buffer, pH 9.6; Sigma) by overnight incubation at 4 °C. Plates were washed (3x) with 0.05% Tween20 in PBS, and blocked with 1% goat serum in PBS for 1 hour at 37 °C.
- Serum samples and standards (anti-OVA IgGl from Cayman Chemical, Ann Arbor, MI; anti-OVA IgG2c from Chondrex, Redmond, WA) were diluted with 1% goat serum, added to plates, and incubated 2 hours at 37 °C. After washing (3x), plates were incubated for 1 hour at 37 °C with biotinylated secondary antibodies (goat anti-mouse IgGl or IgG2c, 1:20,000 in 1% goat serum; Jackson ImmunoResearch, West Grove, PA). Plates were then washed (3x) and incubated for 30 min with streptavidin-HRP (1:1000 in 1% goat serum; BD Biosciences).
- splenocytes from naive mice were pulsed with 2 pg/ml OVA257-264 (SIINFEKL) peptide, or left unpulsed for 1 h.
- Antigen pulsed splenocytes were washed and stained with high concentration carboxyfluorescein succinimidyl ester (CFSE, 10 pM), while unpulsed splenocytes were labeled with low concentration CFSE (1 mM) for 15 min at 37 °C.
- CFSE carboxyfluorescein succinimidyl ester
- a 1:1 mixture of pulsed target cells and unpulsed control cells was intravenously (IV) injected into immunized and naive mice.
- % Lysis ⁇ 1 - [(mean CFSElow/CFSEhigh ratio from naive mice) / (CFSElow/CFSEhigh ratio from vaccinated mouse)] ⁇ x 100.
- the MNAs described herein can be used for a broad range of intradermal and non-cutaneous (e.g., ocular and cardiac tissues) drug delivery applications.
- the biocargo of interest can be located at the very tip of microneedles in the spin-casting process (i.e., a portion of a pyramid) or the entire pyramid region can be loaded with the biocargo depending on the dose requirements.
- FIG. 7A shows PVP/PVA MNAs incorporating Texas Red labeled Dextran (approximately 40 kDa molecular weight) at the tips of microneedles
- FIG. 7B shows tip-loaded CMC/Treh MNAs integrating Allura Red R40 dye (approximately 500 Da molecular weight) at the pyramid region of microneedles.
- FIG. 7C shows tip-loaded PVP/PVA MNAs incorporating multiple cargos such as Texas Red labeled Dextran and Allura Red R40 dye
- FIG. 7D shows tip-loaded PVP/PVA MNAs incorporating multiple cargos such as Texas Red-labeled Dextran and Alexa488-labeled PLGA microparticles (10 pm mean diameter).
- FIGS. 7 A and 7C show the MNAs obtained after the first and twelfth cycles using t, respectively.
- FIGS. 7 A and 7C show the MNAs obtained after the first and twelfth cycles using t, respectively.
- Additive manufacturing or 3D printing as used in the systems and methods described herein provides for accurate and reproducible manufacturing of 3D complex geometries without design limitations and offers a high degree of design flexibility and control. Using the systems and methods here, rapid design-to-fabrication turnaround for optimal application-driven drug delivery systems is possible. [0122] Diverse Needle Geometries
- FIGS. 8A-8B show that this technology enables fabrication of a wide range of microneedle geometries with high-fidelity towards application-driven optimization. Furthermore, as shown in FIGS. 8A-8B, it allows a wide range of design changes, including height, width, apex angle, and geometry of the microneedles without requiring complex and custom processing steps. As such, this technology paves the way for design and fabrication of application-driven unique MNA designs.
- MNAs tip-loaded with Allura Red R40 dye were manufactured using the presented fabrication strategy. Human skin explants were prepared as described above. Allura Red R40 dye loaded MNAs were applied to living human skin explants and removed after 10 min. Images of these MNAs before (FIG. 9A) and after (FIG. 9B) application demonstrated high-quality MNAs and the complete dissolution of the microneedles, respectively. The corresponding deposits of MNA-embedded cargo (e.g., Allura Red R40 dye) in the targeted skin was shown in FIG. 9C.
- MNA-embedded cargo e.g., Allura Red R40 dye
- 9D-I DAPI nuclear stain, Alexa488- labeled Poly(FC), Alexa555-labeled OVA, Brightfield, overlay of 3 different fluorescent colors, merged image of all the fluorescent images with the brightfield image, respectively).
- the scale bars correspond to 100 pm.
- CMC/Treh MNAs with high-fidelity undercut microneedles incorporating both Alexa555-labeled OVA and Alexa488-labeled Poly(I:C) were fabricated as described above.
- Alexa555- OVA+Alexa488-Poly(I:C) MNAs were imaged using bright-field optical microscopy and epi- fluorescent microscopy (FIG. 10A). MNAs were then applied to mice and removed after 10 min. The remaining MNA material after applications was also imaged using bright-field optical microscopy (FIG. 10B).
- MNA-treated mice were imaged using the IVIS 200 live animal imaging system with filters for both Alexa488-Poly(I:C) and Alexa555-OVA.
- MNA-directed co-delivery of Poly(FC) and OVA were shown in FIGS. IOC and 10D, respectively. Together, these images demonstrated successful application of novel MNAs in vivo in mice, and in turn, MNA-directed effective cutaneous drug and vaccine delivery with new MNA designs.
- cytotoxic-T-cell CTL
- antibody responses were quantified using the standard in vivo lytic assay and ELISA, respectively.
- Cutaneous vaccination with MNAs elicited robust antigen- specific cellular immune responses (FIGS. 11A-B).
- equivalent numbers of antigen- pulsed (CFSEhigh) target cells and unpulsed (CFSElow) target cells were recovered from naive or unimmunized mice (FIG. 11 A), thereby indicating the absence of antigen- specific cytolytic activity.
- CFSEhigh antigen- pulsed
- CFSElow unpulsed target cells were recovered from naive or unimmunized mice (FIG. 11 A), thereby indicating the absence of antigen- specific cytolytic activity.
- specific lysis of antigen-pulsed target cells was dramatically enhanced in immunized mice, as shown by reduced survival of OVA-pulsed targets than unpulsed targets.
- mice immunized with OVA-MNA demonstrated greater OVA- specific lysis in vivo, with significantly (as compared to IM-OVA) lower survival and recovery of OVA pulsed targets than unplused targets (FIG. 11 A).
- Immunization with OVA+Poly(I:C) further improved the performance of vaccination (FIG. 11 A).
- Quantification of antigen specific lysis by standard techniques confirmed that MNA immunization elicited potent CTL immunity (FIG. 11B), which was further improved by the inclusion of the adjuvant Poly(I:C).
- targeting skin APCs using MNAs can be an effective strategy for vaccination in general, and in particular for the induction of cell mediated immune responses, including CTL responses essential to prevent or treat many infectious diseases and cancer.
- the presented MNA technology could enable capability relevant to a broad range of vaccination strategies.
- novel dissolving MNAs with undercut microneedles provide for effective intradermal vaccination.
- the unique MNA designs include pyramid heads and undercut stem regions with filleted bases.
- the manufacturing approach to create the undercut MNAs strategically involved 3D laser printing and a number of micromolding processes.
- Successful and reproducible fabrication of dissolvable MNAs with undercut needles that incorporate a myriad of biocargos was achieved using different biocompatible and water-soluble polymers.
- the unprecedented level of geometric capability with 3D laser printing was demonstrated towards application-driven MNA designs for several cutaneous and non-cutaneous drug delivery applications.
- the introduced novel MNAs with undercut features fulfilled strength requirements for failure-free skin penetration in humans and mice, and successfully delivered their biocargos to targeted cutaneous microenvironments.
- cutaneous vaccination using the model antigen-loaded MNAs elicited significantly more potent antigen-specific cellular and humoral immune responses than those obtained by traditional intramuscular injection (IM-OVA) based immunization.
- IM-OVA intramuscular injection
- MNA-directed co-delivery of the antigen (OVA) with the adjuvant (Poly(LC)) improved the immunogenicity of the vaccine with respect to IM-based vaccination towards enhanced MNA-directed cutaneous vaccination.
- the presented approach provides an effective means of fabricating novel dissolving MNAs for a broad range of cutaneous and non-cutaneous drug delivery applications.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Mechanical Engineering (AREA)
- Biomedical Technology (AREA)
- Manufacturing & Machinery (AREA)
- Anesthesiology (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20806768.6A EP3969099A4 (en) | 2019-05-16 | 2020-05-15 | Microneedle arrays with undercut features for cutaneous and non-cutaneous drug delivery |
JP2021568014A JP2022532215A (en) | 2019-05-16 | 2020-05-15 | Microneedle array with undercut features for skin and non-skin drug delivery |
CN202080035822.7A CN113874065A (en) | 2019-05-16 | 2020-05-15 | Microneedle arrays with undercut features for dermal and non-dermal drug delivery |
AU2020275934A AU2020275934A1 (en) | 2019-05-16 | 2020-05-15 | Microneedle arrays with undercut features for cutaneous and non-cutaneous drug delivery |
US17/611,486 US20220241570A1 (en) | 2019-05-16 | 2020-05-15 | Microneedle arrays with undercut features for cutaneous and non-cutaneous drug delivery |
CA3138521A CA3138521A1 (en) | 2019-05-16 | 2020-05-15 | Microneedle arrays with undercut features for cutaneous and non-cutaneous drug delivery |
BR112021022680A BR112021022680A2 (en) | 2019-05-16 | 2020-05-15 | Microneedle arrays with salient features for cutaneous and non-cutaneous drug delivery |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962848939P | 2019-05-16 | 2019-05-16 | |
US62/848,939 | 2019-05-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020232394A1 true WO2020232394A1 (en) | 2020-11-19 |
Family
ID=73289266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/033235 WO2020232394A1 (en) | 2019-05-16 | 2020-05-15 | Microneedle arrays with undercut features for cutaneous and non-cutaneous drug delivery |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220241570A1 (en) |
EP (1) | EP3969099A4 (en) |
JP (1) | JP2022532215A (en) |
CN (1) | CN113874065A (en) |
AU (1) | AU2020275934A1 (en) |
BR (1) | BR112021022680A2 (en) |
CA (1) | CA3138521A1 (en) |
WO (1) | WO2020232394A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021178879A1 (en) * | 2020-03-05 | 2021-09-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | 2019-ncov subunit vaccine and microneedle array delivery system |
WO2022020427A1 (en) * | 2020-07-23 | 2022-01-27 | Microneedles Inc. | Microneedle immunotherapeutic multi-component system and a method for vaccination |
CN114191700A (en) * | 2021-12-17 | 2022-03-18 | 北京理工大学 | Soluble microneedle and medicine feeding device |
WO2023003889A1 (en) * | 2021-07-19 | 2023-01-26 | Carnegie Mellon University | Scalable manufacturing of microneedle arrays using automated high-throughput manufacturing systems and high-capacity molding |
EP4132466A1 (en) * | 2020-04-09 | 2023-02-15 | University of Pittsburgh - of the Commonwealth System of Higher Education | Microneedle array delivery of adenovirus vectored vaccines with and without adjuvants |
WO2023053078A1 (en) * | 2021-09-30 | 2023-04-06 | Scuola Superiore Sant'anna | Device with soluble hook-shaped micro-elements for the deployment of substances into the leaves of plants |
EP4209246A1 (en) * | 2022-01-07 | 2023-07-12 | QuadMedicine, Inc. | Method of manufacturing of a particle-attached microneedle |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130338632A1 (en) * | 2010-10-19 | 2013-12-19 | Trustees Of Tufts College | Silk fibroin-based microneedles and methods of making the same |
US20140200511A1 (en) * | 2009-10-30 | 2014-07-17 | Searete Llc | Systems, devices, and methods for making or administering frozen particles |
US20160158512A1 (en) | 2013-07-30 | 2016-06-09 | Asti Corporation | Microneedle array and microneedle array manufacturing method |
KR101832716B1 (en) | 2016-05-31 | 2018-02-27 | 이승욱 | Micro needle device and it's manufacturing method which can control drug quantity and dosing speed |
US20180333898A1 (en) * | 2017-05-17 | 2018-11-22 | University Medical Pharmaceuticals Corp. | System and method for manufacturing microneedle devices |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014533523A (en) * | 2011-09-02 | 2014-12-15 | ザ レジェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア | Microneedle arrays for biosensing and drug delivery |
KR101712413B1 (en) * | 2013-03-22 | 2017-03-06 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Microneedle applicator comprising a counter assembly |
CN104117137B (en) * | 2014-07-08 | 2017-12-15 | 清华大学 | Unloaded medicine microneedle array and preparation method thereof in a kind of capsule-type |
US10850082B2 (en) * | 2014-09-03 | 2020-12-01 | Newsouth Innovations Pty Limited | Microfluidic devices and fabrication |
US11684763B2 (en) * | 2015-10-16 | 2023-06-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Multi-component bio-active drug delivery and controlled release to the skin by microneedle array devices |
WO2018151832A1 (en) * | 2017-02-17 | 2018-08-23 | Allergan, Inc. | Microneedle array with active ingredient |
CA3070237A1 (en) * | 2017-07-16 | 2019-01-24 | Massachusetts Institute Of Technology | Microneedle tattoo patches and use thereof |
US11844919B2 (en) * | 2018-01-03 | 2023-12-19 | The Trustees Of Columbia University In The City Of New York | Microneedle for local delivery of therapeutic agent |
-
2020
- 2020-05-15 BR BR112021022680A patent/BR112021022680A2/en unknown
- 2020-05-15 AU AU2020275934A patent/AU2020275934A1/en active Pending
- 2020-05-15 CN CN202080035822.7A patent/CN113874065A/en active Pending
- 2020-05-15 US US17/611,486 patent/US20220241570A1/en active Pending
- 2020-05-15 WO PCT/US2020/033235 patent/WO2020232394A1/en active Application Filing
- 2020-05-15 CA CA3138521A patent/CA3138521A1/en active Pending
- 2020-05-15 EP EP20806768.6A patent/EP3969099A4/en active Pending
- 2020-05-15 JP JP2021568014A patent/JP2022532215A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140200511A1 (en) * | 2009-10-30 | 2014-07-17 | Searete Llc | Systems, devices, and methods for making or administering frozen particles |
US20130338632A1 (en) * | 2010-10-19 | 2013-12-19 | Trustees Of Tufts College | Silk fibroin-based microneedles and methods of making the same |
US20160158512A1 (en) | 2013-07-30 | 2016-06-09 | Asti Corporation | Microneedle array and microneedle array manufacturing method |
KR101832716B1 (en) | 2016-05-31 | 2018-02-27 | 이승욱 | Micro needle device and it's manufacturing method which can control drug quantity and dosing speed |
US20180333898A1 (en) * | 2017-05-17 | 2018-11-22 | University Medical Pharmaceuticals Corp. | System and method for manufacturing microneedle devices |
Non-Patent Citations (1)
Title |
---|
See also references of EP3969099A4 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021178879A1 (en) * | 2020-03-05 | 2021-09-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | 2019-ncov subunit vaccine and microneedle array delivery system |
US11213482B1 (en) | 2020-03-05 | 2022-01-04 | University of Pittsburgh—Of the Commonwealth System of Higher Educat | SARS-CoV-2 subunit vaccine and microneedle array delivery system |
US11737974B2 (en) | 2020-03-05 | 2023-08-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | SARS-CoV-2 subunit vaccine and microneedle array delivery system |
EP4132466A1 (en) * | 2020-04-09 | 2023-02-15 | University of Pittsburgh - of the Commonwealth System of Higher Education | Microneedle array delivery of adenovirus vectored vaccines with and without adjuvants |
EP4132466A4 (en) * | 2020-04-09 | 2024-05-15 | University of Pittsburgh - of the Commonwealth System of Higher Education | Microneedle array delivery of adenovirus vectored vaccines with and without adjuvants |
WO2022020427A1 (en) * | 2020-07-23 | 2022-01-27 | Microneedles Inc. | Microneedle immunotherapeutic multi-component system and a method for vaccination |
US11844920B2 (en) | 2020-07-23 | 2023-12-19 | Microneedles Inc | Microneedle immunotherapeutic multi-component system and a method for vaccination |
WO2023003889A1 (en) * | 2021-07-19 | 2023-01-26 | Carnegie Mellon University | Scalable manufacturing of microneedle arrays using automated high-throughput manufacturing systems and high-capacity molding |
WO2023053078A1 (en) * | 2021-09-30 | 2023-04-06 | Scuola Superiore Sant'anna | Device with soluble hook-shaped micro-elements for the deployment of substances into the leaves of plants |
CN114191700A (en) * | 2021-12-17 | 2022-03-18 | 北京理工大学 | Soluble microneedle and medicine feeding device |
CN114191700B (en) * | 2021-12-17 | 2022-08-05 | 北京理工大学 | Soluble microneedle and medicine feeding device |
EP4209246A1 (en) * | 2022-01-07 | 2023-07-12 | QuadMedicine, Inc. | Method of manufacturing of a particle-attached microneedle |
Also Published As
Publication number | Publication date |
---|---|
CN113874065A (en) | 2021-12-31 |
AU2020275934A1 (en) | 2021-12-02 |
EP3969099A4 (en) | 2023-06-21 |
BR112021022680A2 (en) | 2022-03-29 |
JP2022532215A (en) | 2022-07-13 |
EP3969099A1 (en) | 2022-03-23 |
US20220241570A1 (en) | 2022-08-04 |
CA3138521A1 (en) | 2020-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220241570A1 (en) | Microneedle arrays with undercut features for cutaneous and non-cutaneous drug delivery | |
Balmert et al. | Dissolving undercut microneedle arrays for multicomponent cutaneous vaccination | |
Bediz et al. | Dissolvable microneedle arrays for intradermal delivery of biologics: fabrication and application | |
Li et al. | A fast-dissolving microneedle array loaded with chitosan nanoparticles to evoke systemic immune responses in mice | |
Moga et al. | Rapidly–dissolvable microneedle patches via a highly scalable and reproducible soft lithography approach | |
Chen et al. | Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination | |
US20240075267A1 (en) | Microneedle Array Device, Methods Of Manufacturing And Use Thereof | |
Li et al. | Dissolving microneedle arrays with optimized needle geometry for transcutaneous immunization | |
EP2974768A1 (en) | Micro-needle patch | |
CN102325563A (en) | Patch production | |
Ye et al. | Fabrication of tip-hollow and tip-dissolvable microneedle arrays for transdermal drug delivery | |
Bilal et al. | Microneedles in smart drug delivery | |
Koyani | Synthetic polymers for microneedle synthesis: from then to now | |
Lim et al. | Microneedles in action: microneedling and microneedles-assisted transdermal delivery | |
Gamazo et al. | Understanding the basis of transcutaneous vaccine delivery | |
US20160136407A1 (en) | Microneedle arrays for cancer therapy applications | |
Vora et al. | Long-acting microneedle formulations | |
Korkmaz et al. | Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases | |
van der Burg et al. | A low inflammatory, Langerhans cell-targeted microprojection patch to deliver ovalbumin to the epidermis of mouse skin | |
Kenchegowda et al. | Tiny titans-unravelling the potential of polysaccharides and proteins based dissolving microneedles in drug delivery and theranostics: a comprehensive review | |
RU2816629C2 (en) | Microneedle matrices with undercut elements for dermal and non-dermal drug delivery | |
Moffatt et al. | Microneedle technology | |
US20230145599A1 (en) | Microneedle Array Delivery of Adenovirus Vectored Vaccines With and Without Adjuvants | |
Naik et al. | Drug Delivery Through Microneedles for Improved Permeability and Efficacy: Fabrication, Methodology and Applications | |
Kim et al. | Transdermal drug delivery devices based on microneedles: a review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20806768 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3138521 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021568014 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021022680 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020275934 Country of ref document: AU Date of ref document: 20200515 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2020806768 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2020806768 Country of ref document: EP Effective date: 20211216 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112021022680 Country of ref document: BR Free format text: APRESENTAR A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO DA PRIORIDADE US 62/848,939 DE 16/05/2019 OU DECLARACAO CONTENDO, OBRIGATORIAMENTE, TODOS OS DADOS IDENTIFICADORES DESTA CONFORME O ART. 15 DA PORTARIA 39/2021. O DOCUMENTO APRESENTADO NAO ESTA TRADUZIDO E A DECLARACAO NAO CONTEM OS DADOS DA PRIORIDADE. |
|
ENP | Entry into the national phase |
Ref document number: 112021022680 Country of ref document: BR Kind code of ref document: A2 Effective date: 20211111 |